Clinical Trial Update: Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated adjuvant therapy with pegylated interferon-2b in combination with a melanoma peptide vaccine for melanoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Melanoma Peptide Vaccine (melanoma peptide vaccine)
• Pegylated Interferon α-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1 | Status: COMPLETED